IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITCI 76.48 +1.62(2.16%)
Will ITCI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITCI
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Other News for ITCI
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Intra-Cellular price target raised by $6 at Needham, here's why
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Buy Rating Affirmed for Intra-Cellular Therapies with Caplyta Poised for Blockbuster Success
Intra-Cellular just downgraded at UBS, here's why